Scholarlink

<p>Cerebral ischemia–reperfusion injury (CIRI) represents a major contributing factor to adverse outcomes following ischemic stroke (IS), posing significant challenges to patient survival and long-term quality of life. Although various anti-inflammatory and antioxidant agents are currently employed clinically for CIRI treatment, their therapeutic efficacy remains constrained by blood–brain barrier (BBB) limitations and inherent drug limitations, including poor pharmacokinetics and limited in vivo stability. In recent years, nanotechnology has gained increasing prominence in the medical field, with rationally designed nanomedicines demonstrating enhanced BBB permeability and improved bioavailability, emerging as a promising therapeutic approach for CIRI. This review provides a concise overview of the pathological mechanisms underlying CIRI, highlights recent advances in various nanomedicines carrier systems, explores multiple delivery strategies ranging from passive diffusion to active targeting across the BBB, and discusses cutting-edge therapeutic approaches for precision targeting of specific organelles and cellular compartments, with the aim of providing novel insights for subsequent CIRI delivery strategies and therapeutic targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanomedicine-based therapeutic strategies for cerebral ischemia–reperfusion injury: from blood–brain barrier penetration to precision targeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Xiaomeng Guo,
  • Guohao Liu,
  • Yong Liu,
  • Meiling Jin,
  • Zihao Yong,
  • Fukai Li,
  • Shicheng Tang,
  • Liwei Xie,
  • Chunming Huang,
  • Qingchun Mu,
  • He Bai

摘要

Cerebral ischemia–reperfusion injury (CIRI) represents a major contributing factor to adverse outcomes following ischemic stroke (IS), posing significant challenges to patient survival and long-term quality of life. Although various anti-inflammatory and antioxidant agents are currently employed clinically for CIRI treatment, their therapeutic efficacy remains constrained by blood–brain barrier (BBB) limitations and inherent drug limitations, including poor pharmacokinetics and limited in vivo stability. In recent years, nanotechnology has gained increasing prominence in the medical field, with rationally designed nanomedicines demonstrating enhanced BBB permeability and improved bioavailability, emerging as a promising therapeutic approach for CIRI. This review provides a concise overview of the pathological mechanisms underlying CIRI, highlights recent advances in various nanomedicines carrier systems, explores multiple delivery strategies ranging from passive diffusion to active targeting across the BBB, and discusses cutting-edge therapeutic approaches for precision targeting of specific organelles and cellular compartments, with the aim of providing novel insights for subsequent CIRI delivery strategies and therapeutic targets.